Has Matthew Draelos, MD received payments from drug or device companies?

Yes. Drug and device makers reported $392,474 in general payments to Matthew Draelos, MD across 1,394 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Draelos, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Draelos, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Draelos, MD

Endocrinology, Diabetes & Metabolism · Edmond, OKNPI 1437221694

Payments from drug & device makers

$392,474in general payments, 2019–2025

Across 1,394 payments — averaging $281.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Vanda Pharmaceuticals Inc.$283K
Corcept Therapeutics$31K
AstraZeneca$24K
Xeris Pharmaceuticals, Inc.$15K
Merck$8K
Bayer$6K
plus $25K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Vanda Pharmaceuticals Inc.	48	$282,805
Corcept Therapeutics	140	$30,907
AstraZeneca(2 entities)	106	$23,555
Xeris Pharmaceuticals, Inc.	90	$15,363
Merck	57	$8,180
Bayer	77	$6,408
Mannkind Corporation	79	$5,470
Novo Nordisk	122	$2,708
AbbVie	39	$2,099
Amgen(2 entities)	62	$1,545
Amarin Pharma, Inc.	82	$1,308
Dexcom, Inc.	40	$1,103
Madrigal Pharmaceuticals	24	$936
Abbott	27	$889
Sanofi-aventis U.S. LLC	41	$821
Tandem Diabetes Care, Inc.	20	$800
Recordati_rare_diseases_inc.	32	$795
Esperion Therapeutics, Inc.	22	$631
Insulet Corporation	26	$448
Vistapharm, Inc.	36	$438
Clarus Therapeutics Inc.	21	$416
Senseonics, Incorporated	1	$400
Johnson & Johnson(2 entities)	33	$368
IBSA Pharma Inc.	21	$317
Kyowa Kirin, Inc.	9	$313
Antares Pharma, Inc.	16	$307
Novartis	9	$298
Lilly USA, LLC	13	$274
Medtronic	5	$258
Echosens North America, Inc.	2	$231
Shire North American Group Inc	8	$213
EUSA Pharma (US) LLC	12	$191
Althera Pharmaceuticals LLC	4	$133
BETA Bionics, Inc.	6	$129
Regeneron	1	$125
Ascendis Pharma Endocrinology Inc	5	$120
Boehringer Ingelheim	1	$95
Regeneron Healthcare Solutions, Inc.	2	$94
Endo Pharmaceuticals Inc.	7	$93
Astellas Pharma US Inc	4	$88
Currax Pharmaceuticals LLC	4	$74
Radius Health, Inc.	3	$71
Sandoz	2	$66
Zealand Pharma US, Inc.	3	$62
Acella Pharmaceuticals, LLC	3	$48
Ascensia Diabetes Care US Inc.	3	$46
Valeritas, Inc.	3	$45
BD	2	$37
Averitas Pharma Inc.	1	$30
Amryt Pharma Holdings Ltd	2	$29
Lexicon Pharmaceuticals, Inc.	1	$26
Cequr Corporation	3	$25
Pacira Pharmaceuticals Incorporated	1	$22
Gilead	1	$20
Nevro Corp.	1	$19
Rhythm Pharmaceuticals, Inc.	1	$19
GSK	1	$18
Sun Pharmaceutical Industries Inc.	1	$18
Chiesi USA, Inc.	1	$18
Amneal Pharmaceuticals LLC	1	$16

How this compares

$392,474 in reported general payments places this provider in the 95th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.

See all endocrinology, diabetes & metabolism providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$233,990

Medicare patients

757

Services billed

2,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Edmond

Cassie SmithEdmond$629K
Lubna MirzaNorman$837K
Robert ScofieldOklahoma City$189K
Jonea LimOklahoma City$172K
Cristin BrunsTulsa$159K
Donald AspensonTulsa$153K
Christian MangrumOklahoma City$54K
Elie AbedTulsa$27K
Vaqar AhmadMidwest City$27K
Hanna FoggTulsa$25K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →